Product Center

BBL™ CHROMagar™ MRSA II is a selective and differential chromogenic medium for the qualitative direct detection of nasal colonization by methicillin-resistant Staphylococcus aureus (MRSA) to aid in the prevention and control of MRSA infections in healthcare settings. The test is performed on anterior nares swab specimens from patients to screen for MRSA colonization.

BBL CHROMagar MRSA II is not intended to diagnose, guide or monitor treatment for MRSA infections. A negative result does not preclude MRSA nasal colonization. Concomitant cultures are necessary for organism identification, susceptibility testing or epidemiological typing.

MRSA are a major cause of nosocomial and life threatening infections. MRSA infections have been associated with a significantly higher morbidity, mortality and cost compared to methicillin-susceptible S. aureus (MSSA).² Selection of these organisms has been greatest in the healthcare setting; however, MRSA has also become more prevalent in the community.³

To control the transmission of MRSA, the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA) have recommended guidelines, which include monitoring MRSA transmission, infection control programs to control transmission and implementation of active surveillance testing in hospital populations and areas where MRSA is not effectively controlled.²

BBL CHROMagar MRSA II is a selective and differential medium, which incorporates cefoxitin for the detection of MRSA from anterior nares specimens.

BBL CHROMagar MRSA II is a modified version of the existing formulation of BBL CHROMagar MRSA developed by A. Rambach and BD and is sold by BD under a licensing agreement with CHROMagar, Paris, France.

See "Quality Control Procedures."

Quality control requirements must be performed in accordance with applicable local, state and/or federal regulations or accreditation requirements and your laboratory's standard Quality Control procedures. It is recommended that the user refer to pertinent CLSI guidance and CLIA regulations for appropriate Quality Control practices.

Before using BBL CHROMagar MRSA II for the first time, training on the typical colony appearance of MRSA with defined strains (e.g., the strains mentioned under "Quality Control Procedures") is recommended.

For in vitro Diagnostic Use.

If excessive moisture is observed, invert the bottom over an off-set lid and allow to air dry in order to prevent formation of a seal between the top and bottom of the plate during incubation. Protect from light during drying. See storage instructions.

Pathogenic microorganisms, including hepatitis viruses and Human Immunodeficiency Virus may be present in clinical specimens. "Standard Precautions" ^5-8 and institutional guidelines should be followed in handling all items contaminated with blood and other body fluids. After use, prepared plates, specimen containers and other contaminated materials must be sterilized by autoclaving before discarding.